Sector News

BioNTech looking into taking legal steps against CureVac

July 10, 2022
Life sciences

BioNTech is looking into taking legal steps against CureVac after the latter filed a patent lawsuit against it over its use of mRNA technology, BioNTech said on Wednesday, confirming a report by daily Welt.

“We are looking at all legal options,” said a BioNTech spokesperson.

CureVac is seeking “fair compensation” from BioNTech and two subsidiaries for infringement of its intellectual property rights, it said on Tuesday.

BioNTech has said in reaction that its work was original and it would defend it against all allegations of patent infringement.

By Reuters

Source: reuters.com

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.